Long-acting nanoparticulate DNase-1 for effective suppression of SARS-CoV-2-mediated neutrophil activities and cytokine storm
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Y.Y. | - |
dc.contributor.author | Park, H.H. | - |
dc.contributor.author | Park, W. | - |
dc.contributor.author | Kim, H. | - |
dc.contributor.author | Jang, J.G. | - |
dc.contributor.author | Hong, K.S. | - |
dc.contributor.author | Lee, J.-Y. | - |
dc.contributor.author | Seo, H.S. | - |
dc.contributor.author | Na, Dong Hee | - |
dc.contributor.author | Kim, Tae-Hyung | - |
dc.contributor.author | Choy, Y.B. | - |
dc.contributor.author | Ahn, J.H. | - |
dc.contributor.author | Lee, W. | - |
dc.contributor.author | Park, C.G. | - |
dc.date.available | 2020-11-16T05:55:51Z | - |
dc.date.issued | 2021-01 | - |
dc.identifier.issn | 0142-9612 | - |
dc.identifier.issn | 1878-5905 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/43437 | - |
dc.description.abstract | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new strain of coronavirus not previously identified in humans. Globally, the number of confirmed cases and mortality rates of coronavirus disease 2019 (COVID-19) have risen dramatically. Currently, there are no FDA-approved antiviral drugs and there is an urgency to develop treatment strategies that can effectively suppress SARS-CoV-2-mediated cytokine storms, acute respiratory distress syndrome (ARDS), and sepsis. As symptoms progress in patients with SARS-CoV-2 sepsis, elevated amounts of cell-free DNA (cfDNA) are produced, which in turn induce multiple organ failure in these patients. Furthermore, plasma levels of DNase-1 are markedly reduced in SARS-CoV-2 sepsis patients. In this study, we generated recombinant DNase-1-coated polydopamine-poly(ethylene glycol) nanoparticulates (named long-acting DNase-1), and hypothesized that exogenous administration of long-acting DNase-1 may suppress SARS-CoV-2-mediated neutrophil activities and the cytokine storm. Our findings suggest that exogenously administered long-acting nanoparticulate DNase-1 can effectively reduce cfDNA levels and neutrophil activities and may be used as a potential therapeutic intervention for life-threatening SARS-CoV-2-mediated illnesses. © 2020 Elsevier Ltd | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Elsevier Ltd | - |
dc.title | Long-acting nanoparticulate DNase-1 for effective suppression of SARS-CoV-2-mediated neutrophil activities and cytokine storm | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.biomaterials.2020.120389 | - |
dc.identifier.bibliographicCitation | Biomaterials, v.267 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000598391300004 | - |
dc.identifier.scopusid | 2-s2.0-85094326875 | - |
dc.citation.title | Biomaterials | - |
dc.citation.volume | 267 | - |
dc.type.docType | Article | - |
dc.publisher.location | 영국 | - |
dc.subject.keywordAuthor | COVID-19 | - |
dc.subject.keywordAuthor | DNase | - |
dc.subject.keywordAuthor | Nanoparticles | - |
dc.subject.keywordAuthor | NETosis | - |
dc.subject.keywordAuthor | Sepsis | - |
dc.subject.keywordPlus | Polyethylene glycols | - |
dc.subject.keywordPlus | Storms | - |
dc.subject.keywordPlus | Acute respiratory distress syndrome | - |
dc.subject.keywordPlus | Anti-viral drugs | - |
dc.subject.keywordPlus | Effective suppression | - |
dc.subject.keywordPlus | Mortality rate | - |
dc.subject.keywordPlus | Multiple organ failure | - |
dc.subject.keywordPlus | Nano particulates | - |
dc.subject.keywordPlus | Severe acute respiratory syndrome coronavirus | - |
dc.subject.keywordPlus | Therapeutic intervention | - |
dc.subject.keywordPlus | Diseases | - |
dc.relation.journalResearchArea | Engineering | - |
dc.relation.journalResearchArea | Materials Science | - |
dc.relation.journalWebOfScienceCategory | Engineering, Biomedical | - |
dc.relation.journalWebOfScienceCategory | Materials Science, Biomaterials | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.